BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 18321236)

  • 1. Novel therapies targeting the immune system: CTLA4 blockade with tremelimumab (CP-675,206), a fully human monoclonal antibody.
    Camacho LH
    Expert Opin Investig Drugs; 2008 Mar; 17(3):371-85. PubMed ID: 18321236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tremelimumab, a fully human monoclonal IgG2 antibody against CTLA4 for the potential treatment of cancer.
    Tarhini AA; Kirkwood JM
    Curr Opin Mol Ther; 2007 Oct; 9(5):505-14. PubMed ID: 17932815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers.
    Tarhini AA; Kirkwood JM
    Expert Opin Biol Ther; 2008 Oct; 8(10):1583-93. PubMed ID: 18774925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of the CTLA4 blockade in the treatment of malignant melanoma.
    Cranmer LD; Hersh E
    Cancer Invest; 2007 Oct; 25(7):613-31. PubMed ID: 18027152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tremelimumab.
    Drugs R D; 2010; 10(2):123-32. PubMed ID: 20698721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer.
    Ribas A; Hanson DC; Noe DA; Millham R; Guyot DJ; Bernstein SH; Canniff PC; Sharma A; Gomez-Navarro J
    Oncologist; 2007 Jul; 12(7):873-83. PubMed ID: 17673618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma.
    Ralph C; Elkord E; Burt DJ; O'Dwyer JF; Austin EB; Stern PL; Hawkins RE; Thistlethwaite FC
    Clin Cancer Res; 2010 Mar; 16(5):1662-72. PubMed ID: 20179239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications.
    CalabrĂ² L; Danielli R; Sigalotti L; Maio M
    Semin Oncol; 2010 Oct; 37(5):460-7. PubMed ID: 21074061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies.
    O'Day SJ; Hamid O; Urba WJ
    Cancer; 2007 Dec; 110(12):2614-27. PubMed ID: 18000991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206).
    Ribas A
    Oncologist; 2008; 13 Suppl 4():10-5. PubMed ID: 19001146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion.
    Ribas A; Chesney JA; Gordon MS; Abernethy AP; Logan TF; Lawson DH; Chmielowksi B; Glaspy JA; Lewis K; Huang B; Wang E; Hsyu PH; Gomez-Navarro J; Gerhardt D; Marshall MA; Gonzalez R
    J Transl Med; 2012 Nov; 10():236. PubMed ID: 23171508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues.
    Phan GQ; Weber JS; Sondak VK
    Ann Surg Oncol; 2008 Nov; 15(11):3014-21. PubMed ID: 18716842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer.
    Chung KY; Gore I; Fong L; Venook A; Beck SB; Dorazio P; Criscitiello PJ; Healey DI; Huang B; Gomez-Navarro J; Saltz LB
    J Clin Oncol; 2010 Jul; 28(21):3485-90. PubMed ID: 20498386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical development of the anti-CTLA-4 antibody tremelimumab.
    Ribas A
    Semin Oncol; 2010 Oct; 37(5):450-4. PubMed ID: 21074059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.
    Beck KE; Blansfield JA; Tran KQ; Feldman AL; Hughes MS; Royal RE; Kammula US; Topalian SL; Sherry RM; Kleiner D; Quezado M; Lowy I; Yellin M; Rosenberg SA; Yang JC
    J Clin Oncol; 2006 May; 24(15):2283-9. PubMed ID: 16710025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells.
    Vonderheide RH; LoRusso PM; Khalil M; Gartner EM; Khaira D; Soulieres D; Dorazio P; Trosko JA; RĂ¼ter J; Mariani GL; Usari T; Domchek SM
    Clin Cancer Res; 2010 Jul; 16(13):3485-94. PubMed ID: 20479064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment.
    Fong L; Small EJ
    J Clin Oncol; 2008 Nov; 26(32):5275-83. PubMed ID: 18838703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells.
    Khan S; Burt DJ; Ralph C; Thistlethwaite FC; Hawkins RE; Elkord E
    Clin Immunol; 2011 Jan; 138(1):85-96. PubMed ID: 21056008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune modulation in melanoma and advanced cancer therapy: anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibodies.
    Esper P
    Clin J Oncol Nurs; 2009 Oct; 13(5):547-54. PubMed ID: 19793711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Future directions in tumor immunotherapy: CTLA4 blockade.
    Gulley JL; Dahut WL
    Nat Clin Pract Oncol; 2007 Mar; 4(3):136-7. PubMed ID: 17327854
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.